The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of PDS Biotechnology Corporation (NASDAQ: PDSB) closed at $1.16 in the last session, down -5.69% from day before closing price of $1.23. In other words, the price has decreased by -$5.69 from its previous closing price. On the day, 0.8 million shares were traded. PDSB stock price reached its highest trading level at $1.32 during the session, while it also had its lowest trading level at $1.16.
Ratios:
We take a closer look at PDSB’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.33 and its Current Ratio is at 2.33. In the meantime, Its Debt-to-Equity ratio is 0.81 whereas as Long-Term Debt/Eq ratio is at 0.81.
Upgrades & Downgrades
In addition, analysts’ ratings and any changes thereto give investors an idea of the stock’s future direction. In the most recent recommendation for this company, B. Riley Securities on November 01, 2022, initiated with a Buy rating and assigned the stock a target price of $10.
On June 28, 2021, Cantor Fitzgerald started tracking the stock assigning a Overweight rating and target price of $25.
H.C. Wainwright Upgraded its Neutral to Buy on November 10, 2020, while the target price for the stock was maintained at $6.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 28 ’25 when Freitag Gregory Gene bought 15,060 shares for $1.66 per share. The transaction valued at 25,000 led to the insider holds 61,213 shares of the business.
Glover Stephen C. bought 15,061 shares of PDSB for $25,001 on Feb 28 ’25. The Director now owns 78,851 shares after completing the transaction at $1.66 per share.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PDSB now has a Market Capitalization of 53023600 and an Enterprise Value of 35205168.
Stock Price History:
The Beta on a monthly basis for PDSB is 1.14, which has changed by -0.6408669 over the last 52 weeks, in comparison to a change of 0.16657472 over the same period for the S&P500. Over the past 52 weeks, PDSB has reached a high of $4.29, while it has fallen to a 52-week low of $0.85. The 50-Day Moving Average of the stock is -13.81%, while the 200-Day Moving Average is calculated to be -26.86%.
Shares Statistics:
According to the various share statistics, PDSB traded on average about 592.05K shares per day over the past 3-months and 349110 shares per day over the past 10 days. A total of 45.71M shares are outstanding, with a floating share count of 43.98M. Insiders hold about 3.78% of the company’s shares, while institutions hold 19.06% stake in the company. Shares short for PDSB as of 1753920000 were 2273714 with a Short Ratio of 3.84, compared to 1751241600 on 2877317. Therefore, it implies a Short% of Shares Outstanding of 2273714 and a Short% of Float of 5.13.
Dividends & Splits
Against a Trailing Annual Dividend Yield of 0.0
Earnings Estimates
Investors are eagerly awaiting the insights provided by 1.0 analysts currently analyzing and rating the stock of PDS Biotechnology Corporation (PDSB).The consensus estimate for the next quarter is -$0.29, with high estimates of -$0.29 and low estimates of -$0.29.
Analysts are recommending an EPS of between -$0.96 and -$0.96 for the fiscal current year, implying an average EPS of -$0.96. EPS for the following year is -$0.83, with 3.0 analysts recommending between -$0.75 and -$0.9.
